Healthcare & Life Sciences
Aerocrine AB
Sweden
acquiredacquired
acquired
Stage
About
Aerocrine AB developed and commercialized medical technology products for measuring fractional exhaled nitric oxide (FeNO) as an inflammatory marker in patients with inflammatory disorders such as asthma. The company was publicly listed and later acquired by Circassia Pharmaceuticals.
Explore Aerocrine AB's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.